.Monopar Rehabs is recouping a drug coming from the dump of AstraZeneca’s rare ailment pipe. It has actually accredited ALXN-1840, an applicant for the treatment
Read moreAZ describes AI-enabled TROP2 biomarker tactic for Daiichi ADC
.AstraZeneca has actually used artificial intelligence to create an unique biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), hoping to vary the antibody-drug conjugate (ADC)
Read moreAN 2 one-halfs roll call, ceases period 3 test after information let down
.AN2 Rehabs is actually rethinking its organization in feedback to poor midphase data, pledging to give up half its employees and also cease a phase
Read moreALX’s fizzling CD47 feedback cost sends out stock spiraling down
.ALX Oncology’s stage 2 gastric cancer action price has actually deteriorated. After viewing its CD47 blocker effortlessly hammered control over the initial half of the
Read moreAC Immune sees ‘landmark’ potential in Alzheimer’s medicine information
.After more than twenty years of work with neurodegenerative conditions, Swiss biotech AC Immune claims it can have a video game changer on its own
Read more